46 related articles for article (PubMed ID: 28988723)
1. Analysis of the Correlation between FH and PCSK9 and APOB Gene Mutations in Han and Mongolian Populations of the Hulunbuir.
Gao W; Ren Y; Zheng Z; Sun H; Wang J
Clin Lab; 2024 May; 70(5):. PubMed ID: 38747931
[TBL] [Abstract][Full Text] [Related]
2. A human iPSC-derived hepatocyte screen identifies compounds that inhibit production of Apolipoprotein B.
Liu JT; Doueiry C; Jiang YL; Blaszkiewicz J; Lamprecht MP; Heslop JA; Peterson YK; Carten JD; Traktman P; Yuan Y; Khetani SR; Twal WO; Duncan SA
Commun Biol; 2023 Apr; 6(1):452. PubMed ID: 37095219
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Landscape of Familial Hypercholesterolemia: Unraveling Genetic Complexity and Clinical Implications.
Barkas F; Liberopoulos E; Rizzo M
Eur J Intern Med; 2024 May; 123():58-59. PubMed ID: 38443262
[No Abstract] [Full Text] [Related]
4. Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia.
Hindi NN; Alenbawi J; Nemer G
J Pers Med; 2021 Aug; 11(9):. PubMed ID: 34575654
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.
Defesche JC; Stefanutti C; Langslet G; Hopkins PN; Seiz W; Baccara-Dinet MT; Hamon SC; Banerjee P; Kastelein JJP
J Clin Lipidol; 2017; 11(6):1338-1346.e7. PubMed ID: 28964736
[TBL] [Abstract][Full Text] [Related]
7. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
[TBL] [Abstract][Full Text] [Related]
8. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: A case report.
Andersen L; Davis T; Testa H; Andersen RL
J Clin Lipidol; 2017; 11(6):1471-1474. PubMed ID: 28988723
[TBL] [Abstract][Full Text] [Related]
10. Familial defective apolipoprotein B-100: A review.
Andersen LH; Miserez AR; Ahmad Z; Andersen RL
J Clin Lipidol; 2016; 10(6):1297-1302. PubMed ID: 27919345
[TBL] [Abstract][Full Text] [Related]
11. [Molecular genetics of hypercholesterolemia].
Schwarzová L
Vnitr Lek; 2016; 62(11):877-881. PubMed ID: 28128573
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
